For healthcare professionals. Not medical advice.
On this page (10 sections)
- Does overseas approval mean a drug can be used in Singapore?
- What is the Special Access Route for patients?
- Who can apply, and who is the Requester?
- Named-patient or buffer stock?
- What does the requesting doctor or dentist have to do?
- What extra step applies to investigational products?
- How is an application processed?
- What are the limits?
- Which other HSA access routes are there?
- Frequently asked questions
In short
Approval overseas does not allow a drug to be supplied in Singapore. For a patient with an unmet medical need, a licensed hospital, clinic or nursing home (or a licensed retail pharmacy acting on a valid prescription, or a licensed company acting for the institution) can apply for HSA approval for each consignment under the Special Access Route. HSA does not assess these products, and the requesting doctor or dentist is fully responsible for their use.
At a glance
RouteHSA Special Access Route, import for patients' use
Who appliesLicensed hospital, clinic or nursing home, licensed retail pharmacy, or a company acting for an institution
HSA target14 working days, excluding stop-clock time
FeeNone
Validity6 months named patient; 12 months buffer stock
Does overseas approval mean a drug can be used in Singapore?
No. HSA describes products that are not registered here as unregistered therapeutic products, and hospitals, clinics or nursing homes need approval from HSA before importing them for patients' use. Approval elsewhere does not register a product in Singapore.
Check the register firstRegistration status changes. Before considering any import, check the current HSA register of health products, because the route below is intended only where there is an unmet medical need and a registered treatment option is absent. Search the HSA register →
What is the Special Access Route for patients?
In specific situations, HSA may allow the import or supply of therapeutic products through Special Access Routes (SAR). The route for patients is for hospitals, clinics or nursing homes that need HSA approval before importing unregistered therapeutic products for patients' use. HSA states the conditions as follows.
- The use of unregistered therapeutic products should only be considered for life-saving therapies, where there is an unmet medical need, such as where a registered treatment option is absent and the patient's health will be clinically compromised without treatment with the unregistered therapeutic product.
- The safety, quality and efficacy of these products are not assessed by HSA, so requesting doctors or dentists are fully responsible for the use of such products on patients.
- Approval must be obtained for each consignment before it can be imported.
Who can apply, and who is the Requester?
An applicant can apply to import unregistered therapeutic products via this route if they are one of the following.
- A licensed hospital, clinic or nursing home importing the drug for use by its own doctors or dentists on patients under their care. These are specified healthcare service licensees under the Healthcare Services Act 2020.
- A licensed retail pharmacy acting on behalf of, and in accordance with a valid prescription issued by, a registered doctor or dentist.
- A company acting on behalf of a licensed hospital, clinic or nursing home. It must obtain an importer's licence and a wholesaler's licence from HSA before the import, and at least one qualified pharmacist must be named as the responsible person in the import licence.
The applicant is the person importing the product and completes the application form. The doctor, dentist, pharmacist, hospital, clinic or nursing home requesting the product is the Requester. The Requester does not need to access the application form, but the applicant must obtain the Requester's signed request before submitting the online application.
Named-patient or buffer stock?
The application type is determined by the purpose of the request. Each unregistered product needs a separate application form.
| Named-patient | Buffer stock |
| Purpose | To import and supply an unregistered product that presents a life-saving treatment option to a patient whose condition would be clinically compromised without it and for whom no effective alternative therapy is registered in Singapore; or a novel unregistered product that offers a substantive clinical advantage over registered therapies and is expected to provide significant improvement in the patient's clinical outcome. | To import and supply an unregistered product that is a standard essential medicine on the MOH Standard Drugs List, kept as stock in hospitals, clinics or nursing homes; or one on the Hospital Pharmacy and Therapeutics List, kept as stock in hospitals, to meet critical needs. |
| Consignment approval validity | 6 months | 12 months |
| Quantity cap | Each consignment cannot exceed three months' supply per patient, based on the recommended dose in the package insert. A larger quantity may be considered if substantively justified on medical needs. | No per-patient cap stated; this type is held as institutional stock |
What does the requesting doctor or dentist have to do?
For a named-patient application, the application must be accompanied by the clinical justification of the unmet medical need and the reasons for not using current registered therapeutic products. HSA sets these conditions.
- The clinician must obtain and document informed consent from the patient or the patient's guardian for the use of the unregistered product.
- The clinician must furnish a declaration that the use complies with the Ministry of Health's allowable practice and applicable law.
- The clinician must furnish a declaration that the use complies with the clinical practice allowed under the Singapore Medical or Dental Council's Ethical Code and Ethical Guidelines.
Each application must also carry the signed request for the relevant application type, completed and signed by each Requester. In it, the Requester declares that they assume full responsibility for the use of the product on the patient.
What extra step applies to investigational products?
Where the product is investigational, still undergoing testing in a clinical trial, the application should be accompanied by documentary proof of professional consensus. HSA refers to Section B6 paragraph 4 of the Singapore Medical Council (SMC) Ethical Code and Ethical Guidelines and Section B6.1 of the SMC Handbook on Medical Ethics, on the use of innovative therapies in a dire clinical situation. Consensus may come from one or more local peer clinicians and may take the form of email correspondence or other documentation. The requesting clinician must meet one of these two options.
- Consensus obtained from a multidisciplinary team or tumour board within the healthcare institution.
- Consensus obtained from one or more independent clinicians with the relevant medical specialty, practising at a separate healthcare institution under a different Healthcare Services Act licence and not directly involved in the patient's care. They must declare that they have no conflict of interest.
What counts as investigationalHSA defines an investigational therapeutic product as an unregistered product that meets any one of these.
- It is not approved by any HSA reference agency.
- It is rejected, withdrawn or pending deferral for safety or efficacy reasons by any HSA reference agency.
- The clinician's intended use is not approved by any HSA reference agency, and is not documented in established clinical practice guidelines or accepted in current clinical practice as standard of care.
How is an application processed?
1
The Requester signs a request
Each Requester completes and signs the signed request for the relevant application type, named-patient or buffer stock.
2
The applicant submits the online form
The applicant completes the online application form, Sections A to E, using Corppass. Up to 2 requests for the same application type and the same product can be submitted in one application. The applicant must have the Requester's signed request before submitting.
3
Product labels for a first application
Outer and inner labels and the package insert must be submitted for the first application of a product. They are not required for later applications for the same product unless the labels change. Labels must be in English and include the following.
- The proprietary name of the therapeutic product.
- The name and quantities of any active ingredient.
- A control number, such as a serial, batch or lot number.
- The expiry date.
- A declaration that the product contains tartrazine, benzoic acid or sodium benzoate, if applicable.
4
A reference number is issued
On successful submission the applicant receives an email acknowledgment with the application details and a unique 24 alpha-numeric character reference number, to be quoted in any correspondence with HSA.
5
HSA reviews and notifies the outcome
The target turn-around-time is 14 working days, excluding stop-clock time when HSA requests clarification or additional information. The outcome is notified by email. For an approved application, the reference number also serves as the consignment approval number. No fee applies.
6
Correcting errors
Changes cannot be made once the application is submitted. If there are errors, the applicant can withdraw the application and submit a new one.
What are the limits?
- HSA does not assess the safety, quality or efficacy of these products. The requesting doctor or dentist is fully responsible for their use on patients.
- Approval is needed for each consignment before import.
- A product that contains a controlled drug needs a licence to import and wholesale controlled drugs, and one that contains a psychotropic substance needs an approval to import therapeutic products containing psychotropic substances.
- The route is described as being for unmet medical need and not as a route to general supply.
Which other HSA access routes are there?
HSA's overview page lists these further Special Access Routes.
- Special consignment by a product registrant: registrants need HSA approval to bring in a consignment of a registered therapeutic product intended for another market, to mitigate stock-out situations.
- Import of a registered product on a consignment basis: importers who are neither the registrants nor authorised by the registrant need an approval to import a registered drug.
- Pandemic Special Access Route (PSAR): an interim authorisation that lets HSA respond with more flexibility in an emergency that may pose serious threats to the public, such as a pandemic.
Frequently asked questions
Does approval overseas allow a drug to be supplied in Singapore?
No. Approval elsewhere does not register a product in Singapore. Hospitals, clinics or nursing homes need approval from HSA before importing unregistered therapeutic products for patients' use, and approval must be obtained for each consignment.
Who is the Requester in a Special Access Route application?
The Requester is the doctor, dentist, pharmacist or the hospital, clinic or nursing home that is requesting the unregistered therapeutic product. The applicant is the person importing it and completes the online application form. The Requester signs a request declaring full responsibility for the use of the product, and the applicant must obtain it before submitting.
How long does HSA take to process an application, and is there a fee?
HSA's target turn-around-time is 14 working days, excluding stop-clock time when it requests clarification or additional information. The outcome is notified by email. Fee is not applicable.
Does HSA assess the safety, quality or efficacy of these products?
No. HSA does not assess the safety, quality or efficacy of unregistered therapeutic products supplied through this route, so the requesting doctors or dentists are fully responsible for the use of such products on patients.
Published 17 November 2026 | Innorini Regulatory Team | Based on HSA guidance current at the time of writing. Requirements change; check hsa.gov.sg before relying on this page. For healthcare professionals. Not medical or regulatory advice.